Biology:LAG3

From HandWiki
A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene.[1] LAG3, which was discovered in 1990[2] and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000,[3] is a cell surface molecule with diverse biologic effects on T cell function. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right.[4]

Gene

The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4.[1] The gene for LAG-3 lies adjacent to the gene for CD4 on human chromosome 12 (12p13) and is approximately 20% identical to the CD4 gene.[5]

Protein

The LAG3 protein, which belongs to immunoglobulin (Ig) superfamily, comprises a 503-amino acid type I transmembrane protein with four extracellular Ig-like domains, designated D1 to D4. When human LAG-3 was cloned in 1990 it was found to have approx. 70% homology with murine LAG3.[2] The homology of pig LAG3 is 78%.[6]

Tissue distribution

LAG-3 is expressed on activated T cells,[7] natural killer cells,[2] B cells[8] and plasmacytoid dendritic cells.[9]

Function

LAG3's main ligand is MHC class II, to which it binds with higher affinity than CD4.[10] The protein negatively regulates cellular proliferation, activation,[11] and homeostasis of T cells, in a similar fashion to CTLA-4 and PD-1[12][13] and has been reported to play a role in Treg suppressive function.[14]

Fibrinogen-like protein1 FGL1, a liver-secreted protein, is another (major) LAG3 functional ligand independent of MHC-II.[15]

LAG3 also helps maintain CD8+ T cells in a tolerogenic state[5] and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection.[16]

LAG3 is known to be involved in the maturation and activation of dendritic cells.[17]

Use as a pharmaceutical and as a drug target

There are three approaches involving LAG3 that are in clinical development.

  • The first is IMP321,[18] a soluble LAG3 which activates dendritic cells.[19]
  • The second are antibodies to LAG3 which take the brakes off the anti-cancer immune response.[4] An example is relatlimab, an anti-LAG3 monoclonal antibody that is currently in phase 2 clinical testing.[20] A number of additional LAG3 antibodies are in preclinical development.[21] LAG-3 may be a better checkpoint inhibitor target than CTLA-4 or PD-1 since antibodies to these two checkpoints only activate effector T cells, and do not inhibit Treg activity, whereas an antagonist LAG-3 antibody can both activate T effector cells (by downregulating the LAG-3 inhibiting signal into pre-activated LAG-3+ cells) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.[22] Combination therapies are also ongoing involving LAG-3 antibodies and CTLA-4 or PD-1 antibodies.[4][20]
  • The third are agonist antibodies to LAG3 in order to blunt an autoimmune response. An example of this approach is GSK2831781 which has entered clinical testing (for plaque psoriasis).[23]

History

1990 to 1999

LAG3 was discovered in 1990 by Frédéric Triebel (currently Chief Scientific Officer at Immutep) when he headed the cellular immunology group in the Department of Clinical Biology at the Institut Gustave Roussy.[24] An initial characterization of the LAG-3 protein was reported in 1992 showing that it was a ligand for MHC class II antigens[25] while a 1995 paper showed that it bound MHC Class II better than CD4.[10] In 1996 INSERM scientists from Strasbourg showed, in knockout mice that were deficient in both CD4 and LAG-3, that the two proteins were not functionally equivalent.[26] The first characterization of the MHC Class II binding sites on LAG-3 were reported by Triebel's group in 1997.[27] The phenotype of LAG-3 knockout mice, as established by the INSERM Strasbourg group in 1996, demonstrated that LAG-3 was vital for the proper functioning of natural killer cells[28] but in 1998 Triebel, working with LAG-3 antibodies and soluble protein, found that LAG-3 did not define a specific mode of natural killing.[29]

In May 1996 scientists at the University of Florence showed that CD4+ T cells that were LAG-3+ preferentially expressed IFN-γ, and this was up-regulated by IL-12[30] while in 1997 the same group showed that IFN-γ production was a driver of LAG-3 expression during the lineage commitment of human naive T cells.[31] Subsequent work at the Sapienza University of Rome in 1998 showed that IFN-γ is not required for expression but rather for the up-regulation of LAG-3.[32] The Triebel group in 1998 established that LAG-3 expression on activated human T cells is upregulated by IL-2, IL-7 and IL-12 and also showed that expression of LAG-3 may be controlled by some CD4 regulatory elements.[33] In 1998 the Triebel group showed that, on T cells, LAG-3 down-modulates their proliferation and activation when LAG-3/MHC Class II co-caps with CD3/TCR complex.[34] This relationship was confirmed in 1999 with co-capping experiments and with conventional fluorescence microscopy.[35] In 1999 Triebel showed that LAG-3 could be used as a cancer vaccine, through cancer cell lines transfected with LAG-3.[36]

2000 to 2009.

In 2001 the Triebel group identified a LAG3-associated protein, called LAP, that seemed to participate in immune system down-regulation.[37] Also in 2001 the Triebel group reported finding LAG3 expression on CD8+ tumor-infiltrating lymphocytes, with this LAG3 contributing to APC activation.[38] In August 2002 the first phenotypic analysis of the murine LAG-3 was reported by a team at St. Jude Children's Research Hospital in Memphis.[39] Molecular analysis reported by the St. Jude Children's Research Hospital team in November 2002 demonstrated that the inhibitory function of LAG-3 is performed via the protein's cytoplasmic domain.[40] In 2003 the Triebel group was able to identify the MHC class II signal transduction pathways in human dendritic cells induced by LAG3.[41] while the St. Jude Children's Research Hospital team showed that the absence of LAG3 caused no defect in T cell function.[12]

In May 2004 the St. Jude Children's Research Hospital team showed, through LAG3 knockout mice, that LAG-3 negatively regulates T cell expansion and controls the size of the memory T cell pool.[13] This was in spite of earlier in vitro work that seemed to suggest that LAG-3 was necessary for T cell expansion.[12] Work at Johns Hopkins University published in October 2004 identified LAG3's key role in regulatory T cells.[14] The St. Jude Children's Research Hospital team reported in December 2004 that LAG-3 is cleaved within the D4 transmembrane domain into two fragments that remain membrane-associated: a 54-kDa fragment that contains all the extracellular domains and oligomerizes with full-length LAG-3 (70 kDa) on the cell surface via the D1 domain, and a 16-kDa peptide that contains the transmembrane and cytoplasmic domains and is subsequently released as soluble LAG-3.[42]

In January 2005 scientists at the D'Annunzio University of Chieti–Pescara showed that LAG-3 expression by tumour cells would recruit APCs into the tumour which would have Th1 commitment.[43] Scientists working with AstraZeneca reported in March 2005 that SNPs on LAG3 conferred susceptibility to multiple sclerosis[44] although later work at the Karolinska Institute showed no significant association.[45] In June 2005 the Triebel group showed that antibodies to LAG-3 would result in T cell expansion, through increased rounds of cell division which LAG-3 signalling would otherwise block.[46] In July 2005 scientists at the Institute for Research in Biomedicine in Bellinzona established that LAG3 expression on B cells is induced by T cells[8]

In 2006 scientists at the Istituto Superiore di Sanità in Rome showed that LAG could be used as a biomarker to assess the induction of Th-type responses in recipients of acellular pertussis vaccines.[47]

In April 2007 scientists working at Edward Jenner Institute for Vaccine Research in the UK demonstrated that LAG-3 participates in Treg-induced upregulation of CCR7 and CXCR4 on dendritic cells, resulting in semi-mature dendritic cells with the ability to migrate into lymphoid organs.[48] Scientists at Sun Yat-sen University in China showed that LAG-3 played a role in immune privilege in the eye.[49] In late 2007 the St. Jude Children's Research Hospital group showed that LAG-3 maintained tolerance to self and tumor antigens not just via CD4+ cells but also via CD8+ cells, independently of LAG-3's role on TReg cells.[50]

In 2009 the St. Jude Children's Research Hospital group reported that LAG3 appeared on plasmacytoid dendritic cells.[9] Scientists at the University of Tokyo showed that LAG-3 was a marker of Tregs that secrete IL-10.[51]

2010 to 2015.

In 2010 scientists at Swiss Federal Institute of Technology in Zurich showed that LAG3 was an exhaustion marker for CD8+ T cells specific for Lymphocytic choriomeningitis virus, but alone did not significantly contribute to T-cell exhaustion.[52] A team at Roswell Park Comprehensive Cancer Center showed that CD8+ Tumor-infiltrating lymphocytes that were specific for NY-ESO-1 were negatively regulated by LAG-3 and PD-1 in ovarian cancer.[53] The St. Jude Children's Research Hospital group reported that most LAG3 was housed intracellularly in multiple domains before rapid translocation to the cell surface potentially facilitated by the microtubule organizing center and recycling endosomes during T-cell activation.[54] Scientists at the Istituto Nazionale dei Tumori in Milan, collaborating with the Triebel group, showed that LAG3 defines a potent regulatory T cell subset that shows up more frequently in cancer patients and is expanded at tumor sites.[55] Geneticists working at the National Cancer Institute reported that SNPs in the LAG3 gene were associated with higher risk of multiple myeloma.[56]

In 2011 scientists studying transplantation biology at Massachusetts General Hospital reported that when antibodies to CD40L induced tolerance in allogeneic bone marrow transplantation, LAG3 was part of the mechanism of action in CD8+ cells.[57] Scientists at INSERM, working with the Triebel group, showed that the binding of MHC class II molecules on melanoma cells to LAG3 would increase resistance to apoptosis, providing evidence that antibodies to LAG3 would be relevant in melanoma.[58] The St. Jude Children's Research Hospital group showed that LAG3 can play a modulating role in autoimmune diabetes.[59] Microbiologists at the University of Iowa demonstrated that blockade of PD-L1 and LAG-3 was a valid therapeutic strategy for Plasmodium infection.[60]

In 2012 the St. Jude Children's Research Hospital group showed that LAG-3 and PD-1 synergistically regulate T-cell function in such a way as to allow an anti-tumoral immune response to be blunted.[61] Scientists at Hanyang University in Seoul showed that tetravalent CTLA4-Ig and tetravalent LAG3-Ig could synergistically prevent acute graft-versus-host disease in animal models.[62] In 2013 scientists at the San Raffaele Scientific Institute in Milan showed that LAG3 was a marker of type 1 Tregs.[63]

In 2014 scientists at Stanford University showed that LAG engagement could diminish alloreactive T cell responses after bone marrow transplantation.[64] A group from the California Department of Public Health identified a subset of HIV-specific LAG3(+)CD8(+) T cells that negatively correlated with plasma viral load.[65] The Istituto Nazionale dei Tumori group, collaborating with Triebel, found LAG3 expression on plasmacytoid dendritic cells is in part responsible for directing an immune-suppressive environment.[66] A group at Korea University in Seoul demonstrated that LAG-3 translocates to the cell surface in activated T cells via the cytoplasmic domain through protein kinase C signaling.[67]

In 2015 scientists at the University of Tokyo showed how LAG3 on Tregs work with TGF beta 3 to suppress antibody production.[68] At Tulane University bacteriologists working at the Tulane National Primate Research Center showed in rhesus macaques that Mycobacterium tuberculosis could work through LAG3 to modulate an anti-bacterial immune response.[69] At National Taiwan University a group showed that LAG3 plays a role in the immunosuppressive capability of Tregs stimulated by Peyer's patch B cells.[70]

References

  1. ↑ 1.0 1.1 "Entrez Gene: LAG3 lymphocyte-activation gene 3". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3902. 
  2. ↑ 2.0 2.1 2.2 "LAG-3, a novel lymphocyte activation gene closely related to CD4". The Journal of Experimental Medicine 171 (5): 1393–405. May 1990. doi:10.1084/jem.171.5.1393. PMID 1692078. 
  3. ↑ "CD antigens 2001". Journal of Leukocyte Biology 70 (5): 685–90. Nov 2001. PMID 11698486. 
  4. ↑ 4.0 4.1 4.2 Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (December 2017). "De-novo and acquired resistance to immune checkpoint targeting" (in en). The Lancet Oncology 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439. 
  5. ↑ 5.0 5.1 "LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems". The Journal of Clinical Investigation 117 (11): 3383–92. Nov 2007. doi:10.1172/JCI31184. PMID 17932562. 
  6. ↑ "Molecular cloning and expression analysis of pig lymphocyte activation gene-3 (LAG-3; CD223)". Veterinary Immunology and Immunopathology 133 (1): 72–9. Jan 2010. doi:10.1016/j.vetimm.2009.07.001. PMID 19631993. 
  7. ↑ "Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand". Immunogenetics 39 (3): 213–7. January 1, 1994. doi:10.1007/bf00241263. PMID 7506235. 
  8. ↑ 8.0 8.1 "Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells". European Journal of Immunology 35 (7): 2081–8. Jul 2005. doi:10.1002/eji.200526090. PMID 15971272. 
  9. ↑ 9.0 9.1 "LAG-3 regulates plasmacytoid dendritic cell homeostasis". Journal of Immunology 182 (4): 1885–91. Feb 2009. doi:10.4049/jimmunol.0800185. PMID 19201841. 
  10. ↑ 10.0 10.1 "CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins". European Journal of Immunology 25 (9): 2718–21. Sep 1995. doi:10.1002/eji.1830250949. PMID 7589152. 
  11. ↑ Huard B, Tournier M, Hercend T, Triebel F, and Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. European journal of immunology. 1994;24(12):3216-21.
  12. ↑ 12.0 12.1 12.2 "The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells". European Journal of Immunology 33 (4): 970–9. Apr 2003. doi:10.1002/eji.200323382. PMID 12672063. 
  13. ↑ 13.0 13.1 "Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo". Journal of Immunology 172 (9): 5450–5. May 2004. doi:10.4049/jimmunol.172.9.5450. PMID 15100286. 
  14. ↑ 14.0 14.1 "Role of LAG-3 in regulatory T cells". Immunity 21 (4): 503–13. Oct 2004. doi:10.1016/j.immuni.2004.08.010. PMID 15485628. 
  15. ↑ "Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3". Cell 176 (1–2): 334–47. Jan 2019. doi:10.1016/j.cell.2018.11.010. PMID 30580966. 
  16. ↑ "Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection". Nature Immunology 10 (1): 29–37. Jan 2009. doi:10.1038/ni.1679. PMID 19043418. 
  17. ↑ "Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)". Journal of Immunology 168 (8): 3874–80. Apr 2002. doi:10.4049/jimmunol.168.8.3874. PMID 11937541. 
  18. ↑ "Oncology Pipeline at Immutep | Immunotherapy Treatment". https://www.immutep.com/pipeline/clinical-pipeline.html#imp. 
  19. ↑ Avice M; Sarfati M; Triebel F; Delespesse G; Demeure CE. (March 1, 1999). "Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells.". J. Immunol. 162 (5): 2748–53. PMID 10072520. 
  20. ↑ 20.0 20.1 Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov
  21. ↑ "Tesaro's Immuno-Oncology Platform". http://www.tesarobio.com/immuno-oncology_portfolio. 
  22. ↑ "Technology Platforms". Immutep LAG-3. http://www.immutep.org/ProductDevelopment/TechnologyPlatform. 
  23. ↑ A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Subjects and Patients With Plaque Psoriasis
  24. ↑ "LAG-3, a novel lymphocyte activation gene closely related to CD4". The Journal of Experimental Medicine 171 (5): 1393–405. May 1990. doi:10.1084/jem.171.5.1393. PMID 1692078. 
  25. ↑ "Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine 176 (2): 327–37. Aug 1992. doi:10.1084/jem.176.2.327. PMID 1380059. 
  26. ↑ "LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice". International Immunology 8 (5): 725–9. May 1996. doi:10.1093/intimm/8.5.725. PMID 8671660. 
  27. ↑ "Characterization of the major histocompatibility complex class II binding site on LAG-3 protein". Proceedings of the National Academy of Sciences of the United States of America 94 (11): 5744–9. May 1997. doi:10.1073/pnas.94.11.5744. PMID 9159144. Bibcode: 1997PNAS...94.5744H. 
  28. ↑ "Independent modes of natural killing distinguished in mice lacking Lag3". Science 272 (5260): 405–8. Apr 1996. doi:10.1126/science.272.5260.405. PMID 8602528. Bibcode: 1996Sci...272..405M. 
  29. ↑ "LAG-3 does not define a specific mode of natural killing in human". Immunology Letters 61 (2–3): 109–12. Apr 1998. doi:10.1016/s0165-2478(97)00170-3. PMID 9657262. 
  30. ↑ "Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production". FASEB Journal 10 (7): 769–76. May 1996. doi:10.1096/fasebj.10.7.8635694. PMID 8635694. 
  31. ↑ "Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells". European Journal of Immunology 27 (9): 2239–44. Sep 1997. doi:10.1002/eji.1830270918. PMID 9341765. 
  32. ↑ "Lymphocyte activation gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations". Journal of Immunology 161 (1): 489–93. Jul 1998. PMID 9647260. 
  33. ↑ "Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II". Immunogenetics 48 (2): 116–24. Jul 1998. doi:10.1007/s002510050411. PMID 9634475. 
  34. ↑ "CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling". Journal of Immunology 161 (8): 4058–65. Oct 1998. PMID 9780176. 
  35. ↑ "The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes". International Immunology 11 (11): 1745–52. Nov 1999. doi:10.1093/intimm/11.11.1745. PMID 10545478. 
  36. ↑ "Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses". European Journal of Immunology 29 (12): 3867–76. Dec 1999. doi:10.1002/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E. PMID 10601994. 
  37. ↑ "LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway". European Journal of Immunology 31 (10): 2885–91. Oct 2001. doi:10.1002/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2. PMID 11592063. 
  38. ↑ "T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts". European Journal of Cancer 37 (13): 1709–18. Sep 2001. doi:10.1016/s0959-8049(01)00184-8. PMID 11527700. 
  39. ↑ "Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)". European Journal of Immunology 32 (8): 2255–63. Aug 2002. doi:10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A. PMID 12209638. 
  40. ↑ "Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3". Journal of Immunology 169 (10): 5392–5. Nov 2002. doi:10.4049/jimmunol.169.10.5392. PMID 12421911. 
  41. ↑ "MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223)". Blood 102 (6): 2130–7. Sep 2003. doi:10.1182/blood-2003-01-0273. PMID 12775570. 
  42. ↑ "Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223)". Journal of Immunology 173 (11): 6806–12. Dec 2004. doi:10.4049/jimmunol.173.11.6806. PMID 15557174. 
  43. ↑ "Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway". The Journal of Pathology 205 (1): 82–91. Jan 2005. doi:10.1002/path.1679. PMID 15586367. 
  44. ↑ "Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis". Genes and Immunity 6 (2): 145–52. Mar 2005. doi:10.1038/sj.gene.6364171. PMID 15674389. 
  45. ↑ "Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations". Journal of Neuroimmunology 180 (1–2): 193–8. Nov 2006. doi:10.1016/j.jneuroim.2006.08.009. PMID 17020785. 
  46. ↑ "The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells". Immunology 115 (2): 170–8. Jun 2005. doi:10.1111/j.1365-2567.2005.02145.x. PMID 15885122. 
  47. ↑ "Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccine". International Journal of Immunopathology and Pharmacology 19 (1): 97–104. January 1, 2006. doi:10.1177/205873920601900109. PMID 16569347. 
  48. ↑ "Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells". Journal of Immunology 178 (7): 4184–93. Apr 2007. doi:10.4049/jimmunol.178.7.4184. PMID 17371975. 
  49. ↑ "CD4+CD25+Tregs express an increased LAG-3 and CTLA-4 in anterior chamber-associated immune deviation". Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie 245 (10): 1549–57. Oct 2007. doi:10.1007/s00417-007-0591-8. PMID 17541623. http://library.wur.nl/WebQuery/wurpubs/369746. 
  50. ↑ "LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems". The Journal of Clinical Investigation 117 (11): 3383–92. Nov 2007. doi:10.1172/JCI31184. PMID 17932562. 
  51. ↑ "CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2". Proceedings of the National Academy of Sciences of the United States of America 106 (33): 13974–9. Aug 2009. doi:10.1073/pnas.0906872106. PMID 19666526. Bibcode: 2009PNAS..10613974O. 
  52. ↑ "On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection". International Immunology 22 (1): 13–23. Jan 2010. doi:10.1093/intimm/dxp107. PMID 19880580. 
  53. ↑ "Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer". Proceedings of the National Academy of Sciences of the United States of America 107 (17): 7875–80. Apr 2010. doi:10.1073/pnas.1003345107. PMID 20385810. Bibcode: 2010PNAS..107.7875M. 
  54. ↑ "Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4". European Journal of Immunology 40 (6): 1768–77. Jun 2010. doi:10.1002/eji.200939874. PMID 20391435. 
  55. ↑ "LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites". Journal of Immunology 184 (11): 6545–51. Jun 2010. doi:10.4049/jimmunol.0903879. PMID 20421648. 
  56. ↑ "Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut". American Journal of Hematology 85 (8): 560–3. Aug 2010. doi:10.1002/ajh.21760. PMID 20568250. 
  57. ↑ "LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L". Blood 117 (20): 5532–40. May 2011. doi:10.1182/blood-2010-11-318675. PMID 21422469. 
  58. ↑ "MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis". Journal of Immunology 186 (9): 5173–83. May 2011. doi:10.4049/jimmunol.1002050. PMID 21441454. 
  59. ↑ "Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3". Journal of Immunology 187 (7): 3493–8. Oct 2011. doi:10.4049/jimmunol.1100714. PMID 21873518. 
  60. ↑ "Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection". Nature Immunology 13 (2): 188–95. Feb 2012. doi:10.1038/ni.2180. PMID 22157630. 
  61. ↑ "Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape". Cancer Research 72 (4): 917–27. Feb 2012. doi:10.1158/0008-5472.CAN-11-1620. PMID 22186141. 
  62. ↑ "Construction, and in vitro and in vivo analyses of tetravalent immunoadhesins". Journal of Microbiology and Biotechnology 22 (8): 1066–76. Aug 2012. doi:10.4014/jmb.1201.01026. PMID 22713982. 
  63. ↑ "Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells". Nature Medicine 19 (6): 739–46. Jun 2013. doi:10.1038/nm.3179. PMID 23624599. 
  64. ↑ "Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation". PLOS ONE 9 (1): e86551. January 27, 2014. doi:10.1371/journal.pone.0086551. PMID 24475140. Bibcode: 2014PLoSO...986551S. 
  65. ↑ "Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral load". AIDS Research and Human Retroviruses 30 (6): 535–41. Jun 2014. doi:10.1089/AID.2012.0195. PMID 24180338. 
  66. ↑ "Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3". The Journal of Investigative Dermatology 134 (7): 1893–902. Jul 2014. doi:10.1038/jid.2014.29. PMID 24441096. 
  67. ↑ "Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling". Journal of Immunology 193 (6): 3101–12. Sep 2014. doi:10.4049/jimmunol.1401025. PMID 25108024. 
  68. ↑ "TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses". Nature Communications 6 (6329): 6329. February 19, 2015. doi:10.1038/ncomms7329. PMID 25695838. Bibcode: 2015NatCo...6.6329O. 
  69. ↑ "LAG3 expression in active Mycobacterium tuberculosis infections". The American Journal of Pathology 185 (3): 820–33. Mar 2015. doi:10.1016/j.ajpath.2014.11.003. PMID 25549835. 
  70. ↑ "Characterization and functional studies of forkhead box protein 3(-) lymphocyte activation gene 3(+) CD4(+) regulatory T cells induced by mucosal B cells". Clinical and Experimental Immunology 180 (2): 316–28. May 2015. doi:10.1111/cei.12583. PMID 25581421. 

Further reading

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.




Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:LAG3&oldid=3636493"